Janz Tyler A, Nagasubramanian Ramamoorthy, Wei Julie L
University of Central Florida College of Medicine, Orlando, FL, USA.
University of Central Florida College of Medicine, Orlando, FL, USA; Division of Hematology/Oncology, Nemours Children's Hospital, Orlando, FL, USA.
Int J Pediatr Otorhinolaryngol. 2019 Mar;118:160-164. doi: 10.1016/j.ijporl.2018.12.033. Epub 2018 Dec 28.
To examine the survival of pediatric tonsillar cancer patients and review a rare case of pediatric tonsillar cancer.
Pediatric patients in the Surveillance, Epidemiology, and End Results (SEER) database were included from 1973 to 2014 based on a diagnosis of tonsillar malignancy using the ICD O-3 tonsil primary site codes of: C09.0, C09.1, C09.8, and C09.9. Patients were included from birth-18 years. Survival analysis was performed using Kaplan-Meier analysis. Additionally, a case of pediatric natural killer (NK) cell tonsillar lymphoma diagnosed and treated at the Nemours Children's hospital in Orlando, Florida is presented.
One hundred forty-one cases of tonsil cancer were identified. The mean age at diagnosis was 9.9 years (SD: 5.1, range: 0.0 (months)-18.0). Ninety five (67.4%) patients were male and 116 (82.3%) had unilateral malignancies. Burkitt lymphoma (32.6%) followed by diffuse large B-cell lymphoma (DLBCL) (27.0%) were the two most common histological types of tonsillar cancers. 79.4% of patients received chemotherapy and 81.6% received surgery as a part of their care. The 5-year disease-specific survival rate was >90% for patient cohorts diagnosed from 1984 to 1993, 1994-2003, and 2004-2014 as compared to 64% for patients diagnosed from 1973 to 1983 (p = 0.01).
Survival rates for pediatric patients with tonsillar cancer are excellent. Pediatric primary tonsil cancer occurred most commonly in adolescent males and usually presents as a unilateral mass. Lymphoma remains the predominant histological type of cancer. Most patients are likely to receive surgery and chemotherapy.
研究儿童扁桃体癌患者的生存率,并回顾一例罕见的儿童扁桃体癌病例。
根据国际疾病分类肿瘤学第三版(ICD O-3)扁桃体原发部位编码C09.0、C09.1、C09.8和C09.9诊断为扁桃体恶性肿瘤,纳入监测、流行病学和最终结果(SEER)数据库中1973年至2014年的儿科患者。纳入出生至18岁的患者。采用Kaplan-Meier分析进行生存分析。此外,还介绍了一例在佛罗里达州奥兰多市的Nemours儿童医院诊断和治疗的儿童自然杀伤(NK)细胞扁桃体淋巴瘤病例。
共确定141例扁桃体癌病例。诊断时的平均年龄为9.9岁(标准差:5.1,范围:0.0(月)-18.0)。95例(67.4%)患者为男性,116例(82.3%)有单侧恶性肿瘤。伯基特淋巴瘤(32.6%)和弥漫性大B细胞淋巴瘤(DLBCL)(27.0%)是扁桃体癌最常见的两种组织学类型。79.4%的患者接受了化疗,81.6%的患者接受了手术作为其治疗的一部分。与1973年至1983年诊断的患者64%的5年疾病特异性生存率相比,1984年至1993年、1994 - 2003年和2004年至2014年诊断的患者队列的5年疾病特异性生存率>90%(p = 0.01)。
儿童扁桃体癌患者的生存率很高。儿童原发性扁桃体癌最常见于青少年男性,通常表现为单侧肿块。淋巴瘤仍然是主要的癌症组织学类型。大多数患者可能接受手术和化疗。